Company news
Zyus Life Sciences Corporation (TSXV:ZYUS) news
Zyus Life Sciences Corporation news releases on 6ix. Latest, Oct 1, 2026: ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial…
Press releases & updates
ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer
October 1, 2026
ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer
October 1, 2026
ZYUS Life Sciences Corporation Announces Planned Release Date for Phase 2a Clinical Trial Results, Annual General Meeting Results and Change in Audit Committee Chair
September 23, 2026
ZYUS Life Sciences Corporation Provides General Business Update and Announces Changes in Executive Leadership
September 15, 2026
Canadian Investment Regulatory Organization Trade Resumption - ZYUS
September 11, 2026
ZYUS Life Sciences Corporation Provides Liquidity and Working Capital Update and Announces Reinstatement to Trading
September 9, 2026
ZYUS Life Sciences Corporation Announces Completion of Secured Loan Financing
August 31, 2026
ZYUS Life Sciences Corporation Announces Closing of Ninth Tranche of Secured Loan Financing
August 18, 2026
ZYUS Life Sciences Corporation Announces Closing of Eighth Tranche of Secured Loan Financing and Amendment to Unsecured Promissory Note
August 12, 2026
ZYUS Life Sciences Corporation Announces Closing of Seventh Tranche of Secured Loan Financing
July 29, 2026
ZYUS Life Sciences Corporation Announces Closing of Sixth Tranche of Secured Loan Financing
July 21, 2026
ZYUS Life Sciences Corporation Announces Revocation of Failure-to-File Cease Trade Order
July 20, 2026
ZYUS Announces Database Lock for its Phase 2a UTOPIA-1 Trial, CFO Transition and Continuous Disclosure Update
July 19, 2026
ZYUS Life Sciences Corporation Announces Closing of Fifth Tranche of Secured Loan Financing
July 1, 2026
ZYUS Life Sciences Corporation Announces Closing of Fourth Tranche of Secured Loan Financing
June 23, 2026
ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing
June 16, 2026
ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development
June 11, 2026
ZYUS Life Sciences Corporation Announces Closing of Second Tranche of Secured Loan Financing and Provides an Update on its Annual Filings and Q1 2026 Financial Statement
May 28, 2026
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Secured Loan Financing and Provides an Update on its Annual Filings
May 19, 2026
Canadian Investment Regulatory Organization Trading Halt - ZYUS
May 7, 2026
ZYUS Announces Cease Trade Order
May 5, 2026
ZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent
May 5, 2026
ZYUS Announces Delay in Its Annual Filings
April 29, 2026
ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
April 16, 2026
ZYUS Life Sciences Provides an Update on Its Unit Offering
April 10, 2026
ZYUS Life Sciences Announces Closing of Debt Financing
March 5, 2026
ZYUS Life Sciences Announces Cancellation of LIFE Offering and Launch of Private Placement
February 23, 2026
ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document
February 9, 2026
ZYUS Life Sciences Announces Amendment to Subleases and Promissory Note Agreement
February 3, 2026
ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units
January 12, 2026
ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug
January 8, 2026
ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement
December 8, 2025
ZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units
December 1, 2025
ZYUS Life Sciences Corporation Announces Closing of First Tranche of Unit Offering and Issuance of Warrants Pursuant to Previously Announced Loan Agreements and Promissory Note Amendment
November 7, 2025
ZYUS Life Sciences Corporation Announces Closing of Additional Secured Loan
October 20, 2025
WAYNE BROWNLEE PROVIDES UPDATE ON HOLDINGS OF ZYUS LIFE SCIENCES CORPORATION
October 17, 2025
BRENT H. ZETTL PROVIDES UPDATE ON HOLDINGS OF ZYUS LIFE SCIENCES CORPORATION
October 17, 2025
ZYUS Life Sciences Corporation Announces Closing of Secured Loan and Amendments to Prior Secured Promissory Note
October 17, 2025
ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial
October 2, 2025
ZYUS Life Sciences Activates First Clinical Site and Enrolls First Patient in Phase 2a UTOPIA-1 Cancer Pain Trial
August 26, 2025
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
August 15, 2025
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
July 29, 2025
ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
July 15, 2025
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
June 27, 2025
ZYUS Life Sciences Announces Closing of Unit Offering
June 27, 2025
 ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
June 16, 2025
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
May 22, 2025
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
May 1, 2025
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
May 1, 2025
ZYUS Life Sciences Corporation Announces Issuance of Bonus Warrants Pursuant to Loan Agreements
April 11, 2025